To include your compound in the COVID-19 Resource Center, submit it here.

Cytokinetics reports additional Phase III data for suspended ALS candidate

Cytokinetics Inc. (NASDAQ:CYTK) reported additional data from the Phase III VITALITY-ALS trial in 744 patients with amyotrophic lateral sclerosis (ALS) showing

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE